Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial.
Saved in:
| Title: | Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial. |
|---|---|
| Authors: | Cook G; Department of Haematology, Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, UK; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK. Electronic address: g.cook@leeds.ac.uk., Ashcroft AJ; Mid-Yorkshire NHS Trust, Wakefield, UK., Senior E; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK., Olivier C; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK., Hockaday A; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK., Richards J; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK., Cavenagh JD; Department of Haematology, Barts Health NHS Trust, London, UK., Snowden JA; Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK; Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, UK., Drayson MT; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK., de Tute R; Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, UK., Roberts L; Leek, UK., Owen RG; Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, UK., Yong K; University College London Hospitals, NHS Foundation Trust, London, UK., Garg M; Leicester Royal Infirmary, Leicester, UK., Boyd K; Department of Haematology, Royal Marsden Hospital, London, UK., Sati H; Department of Haematology, Singleton Hospital, Swansea, UK., Gillson S; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK., Cook M; Bristol-Myers Squibb, Boudry, Switzerland., Cairns DA; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK., Parrish C; Department of Haematology, Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, UK; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK. |
| Corporate Authors: | United Kingdom Myeloma Research Alliance |
| Source: | The Lancet. Haematology [Lancet Haematol] 2024 Nov; Vol. 11 (11), pp. e816-e829. Date of Electronic Publication: 2024 Sep 06. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study |
| Journal Info: | Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3026 (Electronic) Linking ISSN: 23523026 NLM ISO Abbreviation: Lancet Haematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 39250926 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Cook+G%22">Cook G</searchLink>; Department of Haematology, Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, UK; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK. Electronic address: g.cook@leeds.ac.uk.<br /><searchLink fieldCode="AU" term="%22Ashcroft+AJ%22">Ashcroft AJ</searchLink>; Mid-Yorkshire NHS Trust, Wakefield, UK.<br /><searchLink fieldCode="AU" term="%22Senior+E%22">Senior E</searchLink>; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.<br /><searchLink fieldCode="AU" term="%22Olivier+C%22">Olivier C</searchLink>; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.<br /><searchLink fieldCode="AU" term="%22Hockaday+A%22">Hockaday A</searchLink>; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.<br /><searchLink fieldCode="AU" term="%22Richards+J%22">Richards J</searchLink>; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.<br /><searchLink fieldCode="AU" term="%22Cavenagh+JD%22">Cavenagh JD</searchLink>; Department of Haematology, Barts Health NHS Trust, London, UK.<br /><searchLink fieldCode="AU" term="%22Snowden+JA%22">Snowden JA</searchLink>; Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK; Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, UK.<br /><searchLink fieldCode="AU" term="%22Drayson+MT%22">Drayson MT</searchLink>; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.<br /><searchLink fieldCode="AU" term="%22de+Tute+R%22">de Tute R</searchLink>; Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, UK.<br /><searchLink fieldCode="AU" term="%22Roberts+L%22">Roberts L</searchLink>; Leek, UK.<br /><searchLink fieldCode="AU" term="%22Owen+RG%22">Owen RG</searchLink>; Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, UK.<br /><searchLink fieldCode="AU" term="%22Yong+K%22">Yong K</searchLink>; University College London Hospitals, NHS Foundation Trust, London, UK.<br /><searchLink fieldCode="AU" term="%22Garg+M%22">Garg M</searchLink>; Leicester Royal Infirmary, Leicester, UK.<br /><searchLink fieldCode="AU" term="%22Boyd+K%22">Boyd K</searchLink>; Department of Haematology, Royal Marsden Hospital, London, UK.<br /><searchLink fieldCode="AU" term="%22Sati+H%22">Sati H</searchLink>; Department of Haematology, Singleton Hospital, Swansea, UK.<br /><searchLink fieldCode="AU" term="%22Gillson+S%22">Gillson S</searchLink>; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.<br /><searchLink fieldCode="AU" term="%22Cook+M%22">Cook M</searchLink>; Bristol-Myers Squibb, Boudry, Switzerland.<br /><searchLink fieldCode="AU" term="%22Cairns+DA%22">Cairns DA</searchLink>; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.<br /><searchLink fieldCode="AU" term="%22Parrish+C%22">Parrish C</searchLink>; Department of Haematology, Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, UK; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK. – Name: AuthorCorporate Label: Corporate Authors Group: Au Data: <searchLink fieldCode="CA" term="%22United+Kingdom+Myeloma+Research+Alliance%22">United Kingdom Myeloma Research Alliance</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101643584%22">The Lancet. Haematology</searchLink> [Lancet Haematol] 2024 Nov; Vol. 11 (11), pp. e816-e829. <i>Date of Electronic Publication: </i>2024 Sep 06. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Ltd%22">Elsevier Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101643584 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2352-3026 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2223523026%22">23523026 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Haematol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39250926 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/S2352-3026(24)00249-7 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: e816 Titles: – TitleFull: Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Cook G – PersonEntity: Name: NameFull: Ashcroft AJ – PersonEntity: Name: NameFull: Senior E – PersonEntity: Name: NameFull: Olivier C – PersonEntity: Name: NameFull: Hockaday A – PersonEntity: Name: NameFull: Richards J – PersonEntity: Name: NameFull: Cavenagh JD – PersonEntity: Name: NameFull: Snowden JA – PersonEntity: Name: NameFull: Drayson MT – PersonEntity: Name: NameFull: de Tute R – PersonEntity: Name: NameFull: Roberts L – PersonEntity: Name: NameFull: Owen RG – PersonEntity: Name: NameFull: Yong K – PersonEntity: Name: NameFull: Garg M – PersonEntity: Name: NameFull: Boyd K – PersonEntity: Name: NameFull: Sati H – PersonEntity: Name: NameFull: Gillson S – PersonEntity: Name: NameFull: Cook M – PersonEntity: Name: NameFull: Cairns DA – PersonEntity: Name: NameFull: Parrish C IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 11 Text: 2024 Nov Type: published Y: 2024 Identifiers: – Type: issn-electronic Value: 2352-3026 Numbering: – Type: volume Value: 11 – Type: issue Value: 11 Titles: – TitleFull: The Lancet. Haematology Type: main |
| ResultId | 1 |
